ARTICLE | Clinical News
Arbaclofen placarbil: Phase III started
August 8, 2011 7:00 AM UTC
XenoPort disclosed in its 2Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 weeks in about 200 p...